Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
AMP-303 by Amplifica Holdings Group for Androgenic Alopecia: Likelihood of Approval
AMP-303 is under clinical development by Amplifica Holdings Group and currently in Phase I for Androgenic Alopecia. According to GlobalData,...